Moderna Shares Plunge 93% Below All-Time High: Key Levels and Next Price Target

MRNA Stock Analysis

Moderna shares dropped more than 20% on Monday as investors have now done an about-face on the stock.

Over the last two weeks, investors have been acquiring shares of the biopharma company as news of the first human death from Bird Flu hit the headlines.  Moderna is one of two companies that has been developing a vaccination for Bird Flu.

Today’s move wiped out the entirety of last week’s rally plus an additional 15% as investors now question the company’s fundamental strength.

Today’s selling was sparked by an update from the company in which management detailed the progress of their drug pipeline.  During that update, Moderna lowered their Fiscal 2025 revenue target below that of Wall Street’s analyst expectations.

Moderna’s reported revenue has declined 8 out of the last ten quarters, though coming in above analyst expectations over most of the quarters.

Today’s drop in Moderna’s price moves the company’s stock to its lowest levels since April 2020.  Shares now trade 93% lower than their all-time high price of 497.49.

While shares did rally from their intraday lows, the stock is still stuck in an intermediate-term bear market trend that was recently rejected at $40.  The stock’s bearish 50-day moving average currently trades at the stock’s recent highs.

Shares of Moderna remain in a bear market trend with a price target of $25.00.

Recommended